Upur H, Li JL, Zou XG, Hu YY, Yang HY, Abudoureyimu A, et al. Short and long-term prognosis of admission hyperglycemia in patients with and without diabetes after acute myocardial infarction: a retrospective cohort study. Cardiovasc Diabetol. 2022;21(1):114.
Article
CAS
Google Scholar
Zhao Y, Lu X, Wan F, Gao L, Lin N, He J, et al. Disruption of circadian rhythms by shift work exacerbates reperfusion injury in myocardial infarction. J Am Coll Cardiol. 2022;79(21):2097–115.
Article
Google Scholar
Hashimoto Y, Ozaki Y, Kan S, Nakao K, Kimura K, Ako J, et al. Impact of chronic kidney disease on in-hospital and 3-year clinical outcomes in patients with acute myocardial infarction treated by contemporary percutaneous coronary intervention and optimal medical therapy—insights from the J-MINUET study. Circ J. 2021;85(10):1710–8.
Article
Google Scholar
Sacre JW, Magliano DJ, Shaw JE. Clinical utility of cardiovascular risk scores for identification of people with type 2 diabetes more likely to benefit from either GLP-1 receptor agonist or SGLT2 inhibitor therapy. Diabetes care. 2022;45:1900.
Article
CAS
Google Scholar
Wei W, Liu J, Chen S, Xu X, Guo D, He Y, et al. Sodium glucose cotransporter Type 2 inhibitors improve cardiorenal outcome of patients with coronary artery disease: a meta-analysis. Front Endocrinol. 2022;13: 850836.
Article
Google Scholar
Al Rifai M, Newby LK, Nair AP, Misra A, Rogers JG, Fedson S, et al. SGLT-2 inhibitors for patients with heart failure: what have we learned recently? Curr Atheroscler Rep. 2022;24(8):627–34.
Article
CAS
Google Scholar
Sharma A, Ofstad AP, Ahmad T, Zinman B, Zwiener I, Fitchett D, et al. Patient phenotypes and SGLT-2 inhibition in type 2 diabetes: insights from the EMPA-REG OUTCOME trial. JACC Heart failure. 2021;9(8):568–77.
Article
Google Scholar
Kaku K, Wanner C, Anker SD, Pocock S, Yasui A, Mattheus M, et al. The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease. Diabetes Obes Metab. 2022;24(4):662–74.
Article
CAS
Google Scholar
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose Cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022–31.
Article
CAS
Google Scholar
Yu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC heart failure. 2021;8(2):1482–93.
Article
Google Scholar
Yu J, Li J, Leaver PJ, Arnott C, Huffman MD, Udell JA, et al. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. Cardiovasc Res. 2022;118(4):1103–14.
Article
CAS
Google Scholar
Wu Z, Cui H, Li W, Zhang Y, Liu L, Liu Z, et al. Comparison of three non-insulin-based insulin resistance indexes in predicting the presence and severity of coronary artery disease. Front Cardiovasc Med. 2022;9: 918359.
Article
Google Scholar
Han K, Shi D, Yang L, Wang Z, Li Y, Gao F, et al. Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Ann Med. 2022;54(1):1667–77.
Article
CAS
Google Scholar
Wu Z, Liu L, Wang W, Cui H, Zhang Y, Xu J, et al. Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study. Cardiovasc Diabetol. 2022;21(1):142.
Article
CAS
Google Scholar
Zheng Y, Li C, Yang J, Seery S, Qi Y, Wang W, et al. Atherogenic index of plasma for non-diabetic, coronary artery disease patients after percutaneous coronary intervention: a prospective study of the long-term outcomes in China. Cardiovasc Diabetol. 2022;21(1):29.
Article
CAS
Google Scholar
Jhalani NB. Clinical Considerations for use of SGLT2 inhibitor therapy in patients with heart failure and reduced ejection fraction: a review. Adv Ther. 2022;39(8):3472–87.
Article
CAS
Google Scholar
Thiele K, Rau M, Hartmann NK, Möller M, Möllmann J, Jankowski J, et al. Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. ESC Heart Failure. 2022;9(4):2233–8.
Article
Google Scholar
Vukadinović D, Abdin A, Anker SD, Rosano GMC, Mahfoud F, Packer M, et al. Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. Eur J Heart Failure. 2022. https://doi.org/10.1002/ejhf.2584.
Article
Google Scholar
Martinez-Sanchez FD, Medina-Urrutia AX, Jorge-Galarza E, Martínez-Alvarado MDR, Reyes-Barrera J, Osorio-Alonso H, et al. Effect of metabolic control on recurrent major adverse cardiovascular events and cardiovascular mortality in patients with premature coronary artery disease. Results of the genetics of atherosclerotic disease study. Nutr Metab Cardiovas Dis: NMCD. 2022. https://doi.org/10.1016/j.numecd.2022.06.0.
Article
Google Scholar
She J, Lou B, Liu H, Zhou B, Jiang GT, Luo Y, et al. ARNI versus ACEI/ARB in reducing cardiovascular outcomes after myocardial infarction. ESC Heart Failure. 2021;8(6):4607–16.
Article
Google Scholar
Sposito AC, Breder I, Soares AAS, Kimura-Medorima ST, Munhoz DB, Cintra RMR, et al. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovasc Diabetol. 2021;20(1):74.
Article
CAS
Google Scholar
Zhang Y, Lin X, Chu Y, Chen X, Du H, Zhang H, et al. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling. Cardiovasc Diabetol. 2021;20(1):121.
Article
CAS
Google Scholar
Hasan A, Menon SN, Zerin F, Hasan R. Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell K(V)7 ion channels. Heliyon. 2022;8(5): e09503.
Article
Google Scholar
Yang L, Liang B, Li J, Zhang X, Chen H, Sun J, et al. Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK/mTOR mediated autophagy pathway. Cell Signal. 2022;90: 110206.
Article
CAS
Google Scholar
Mone P, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, et al. SGLT2 Inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stres insights from frail hypertensive and diabetic patients. Hypertension (Dallas, Tex : 1979). 2022;79(8):1633–43.
Article
CAS
Google Scholar
Moellmann J, Mann PA, Kappel BA, Kahles F, Klinkhammer BM, Boor P, et al. The SGLT2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR-signaling, endoplasmic reticulum stress and apoptosis. Diabetes, Obes Metab. 2022. https://doi.org/10.1111/dom.14814.
Article
Google Scholar
Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2022;13(5):336–59.
Article
CAS
Google Scholar
Antlanger M, Domenig O, Kaltenecker CC, Kovarik JJ, Rathkolb V, Müller MM, et al. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial. Diabetes Obes Metab. 2022;24(5):816–26.
Article
CAS
Google Scholar
Tricò D, Raggi F, Distaso M, Ferrannini E, Solini A. Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes. Diabetes Res Clin Pract. 2022;190: 109983.
Article
Google Scholar